Ruplizumab Biosimilar, Anti-human CD40L Monoclonal Antibody

Ruplizumab Biosimilar, Anti-human CD40L Monoclonal Antibody

$175.00$1,200.00

In stock

$175.00$1,200.00

The cheapest research grade ruplizumab biosimilar (anti-human CD40L/CD40/CD154 monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying biological pathways affected by ruplizumab. The research grade ruplizumab biosimilar protein is for research use only.

Synonyms: TNFSF5, CD154, CD40 ligand, HIGM1, IGM, IMD3, T-BAM, TNFSF5, TRAP, gp39, hCD40L

SKU: C063P
Clear
View cart
Catalog No. C063P
Product NameRuplizumab Biosimilar, Anti-human CD40L Monoclonal Antibody
Supplier Name Syd Labs, Inc.
Brand Name Syd Labs
Source/Host The anti-human CD40L monoclonal antibody ruplizumab biosimilar was produced in mammalian cells.
Specificity/Sensitivity The in vivo grade ruplizumab biosimilar specifically binds to the human CD40L.
Applications ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by ruplizumab.
Form Of Antibody 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin < 0.1 EU per 1 ug of the protein by the LAL method.
Purity >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping The research grade ruplizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Order Offline Phone: 1-617-401-8149 Fax: 1-617-606-5019 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

C063P: Ruplizumab Biosimilar (Research Grade), Anti-human CD40L Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

Ruplizumab Biosimilar uses the same protein sequences as the therapeutic antibody ruplizumab.

Ruplizumab is a humanized anti-CD40L/CD154 monoclonal antibody. he binding of CD40 to its ligand, CD40L, is a critical element in T cell activation. In systemic lupus erythematosus, CD40L is over-expressed on T cells, B cells, and monocytes. It was intended for the treatment of rheumatic diseases like systemic lupus erythematosus and lupus nephritis, as well as the primary skin allograft rejection. A study showed that the drug was associated with life-threatening thromboembolisms, while another study only found thrombocytopenia. In previous studies, the monoclonal antibody, ruplizumab showed evidence of potential efficacy in patients with lupus nephritis and idiopathic thrombocytopenic purpura. Besides, clinical trials were halted because of a higher than expected occurrence of thromboembolic events. It is proposed that the observed treatment-related (TR) thromboembolic events occurred as a result of platelet activation and aggregation, due to the formation of anti-CD40L antibody and soluble CD40L immune complexes that tether to platelets via binding of sCD40L to surface-expressed CD40 and activate platelets through interactions of the Fc with Fc gamma receptor IIA on the platelet surface.

Modern allotransplantation requires the daily administration of nonspecific immunosuppressive agents to prevent T cell-mediated acute rejection. The agents commonly used include glucocorticosteroids, antiproliferative agents such as azathioprine or mycophenolate mofetil (MMF) and calcineurin inhibitors (tacrolimus or cyclosporine A). Although these agents have considerably improved the outcome of patients receiving solid organ transplants, their therapeutic effects are transient, and all are associated with substantial toxicity. The CD40 ligand (CD40L, also known as CD154) has been shown to be an important modulator of immunoinflammatory events in autoimmune disease and acute allograft rejection. CD40 is expressed constitutively on antigen presenting cells (APCs), including B cells, while CD40L is a member of the tumor necrosis factor family of transmembrane glycoproteins and is expressed on activated CD4þ T cells. The CD40-CD40L interaction is essential for normal T cell–B-cell interactions, including T-cell priming, immunoglobulin (Ig) class-switching, and the T cell-dependent humoral immune response. Indeed, the CD40-CD40L molecules form a co-stimulatory pair, providing the second signal required for T-cell activation of APCs. CD154 binds to CD40 and leads to APC secretion of IL-1β, TNF-α, and IL-12, and to endothelial cell secretion of monocyte chemotactic factors. It also increases APC and endothelial cell expression of MHC class II molecules, of adhesion molecules, and of the co-stimulatory ligands CD80 and CD86. Although blockade of the CD154-CD40 pathway does little to prevent the proliferative response of CD4+ T cells in vitro, it substantially curtails the maturation of cytotoxic CD8+ T cells by interfering with required T-cell-APC interactions. The monoclonal antibody ruplizumab neutralizes CD40L function, as it blocks the interaction between CD40 and CD40L. It has been proven in animal experiments that this drug can prolong rhesus monkey renal allograft survival.

Syd Labs also provides the following anti-CD40 / CD40L antibody biosimilar proteins:
Toralizumab Biosimilar, research grade, anti-human CD40/CD40L/CD154 monoclonal antibody

Syd Labs provides a number of research grade antibody biosimilar proteins with competitive prices starting from $3/mg. Syd Labs also introduces mutations to the antibody biosimilars including engineering or switching the isotypes or Fc engineering, such as Fc silent.

Syd Labs also produces the in vivo grade isotype control antibodies. Some customers purchase them for in vitro assays such as flow cytometry or immunohistochemistry (IHC) because the prices are too good if compared to those research reagents of antibody isotype controls. Syd Labs provides the following in vivo grade recombinant human IgG1 kappa isotype control antibody proteins and mutants:

In vivo grade recombinant human IgG1 isotype control antibody
In vivo grade recombinant human IgG1 Fc protein
In vivo grade recombinant human IgG1-D265A isotype control antibody
In vivo grade recombinant human IgG1-N297A isotype control antibody
In vivo grade recombinant human IgG1-D265A N297A isotype control antibody
In vivo grade recombinant human IgG1-L234A L235A P329G (LALAPG) isotype control antibody

Frequent questions related to “research grade ruplizumab biosimilar, anti-human CD40L/CD154 monoclonal antibody”:

Does ruplizumab bind mouse CD40L?
Does ruplizumab bind mouse CD40?
Does ruplizumab bind mouse CD154?
Is ruplizumab humanized?
What is the mechanism of action for ruplizumab?

Popular searches related to “research grade ruplizumab biosimilar, anti-human CD40L/CD154 monoclonal antibody”:

ruplizumab monoclonal antibody
ruplizumab purchase
ruplizumab mechanism of action
ruplizumab price
CD40L mouse cell line
CD40 mouse cell line
CD154 mouse cell line
Ruplizumab Biosimilar Research Grade
CD40
CD40L
CD154

Additional information

Size

1 mg, 20 mg, 5 mg

No more offers for this product!